Abstract
Spatial transcriptomics enables in-depth molecular characterization of samples on a morphology and RNA level while preserving spatial location. Integrating the resulting multi-modal data is an unsolved problem, and developing new solutions in precision medicine depends on improved methodologies. Here, we introduce AESTETIK, a convolutional deep learning model that jointly integrates spatial, transcriptomics, and morphology information to learn accurate spot representations. AESTETIK yielded substantially improved cluster assignments on widely adopted technology platforms (e.g., 10x Genomics™, NanoString™) across multiple datasets. We achieved performance enhancement on structured tissues (e.g., brain) with a 21% increase in median ARI over previous state-of-the-art methods. Notably, AESTETIK also demonstrated superior performance on cancer tissues with heterogeneous cell populations, showing a two-fold increase in breast cancer, 79% in melanoma, and 21% in liver cancer. We expect that these advances will enable a multi-modal understanding of key biological processes.
Competing Interest Statement
V.H.K reports being an invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs; advisory board of Takeda; and sponsored research agreements with Roche and IAG, all unrelated to the current study. VHK is a participant in a patent application on the assessment of cancer immunotherapy biomarkers by digital pathology; a patent application on multimodal deep learning for the prediction of recurrence risk in cancer patients, and a patent application on predicting the efficacy of cancer treatment using deep learning. GR is a participant in a patent application on matching cells from different measurement modalities which is not directly related to the current work. Moreover, G.R. is a cofounder of Computomics GmbH, Germany, and one of its shareholders.
Funding Statement
We gratefully acknowledge funding from the Tumor Profiler Initiative and the Tumor Profiler Center (to V.H.K., G.R.). The Tumor Profiler study is jointly funded by a public-private partnership involving F. Hoffmann-La Roche Ltd., ETH Zurich, University of Zurich, University Hospital Zurich, and University Hospital Basel. We also acknowledge funding of S.A. from the Swiss Federal Institutes of Technology strategic focus area of personalized health and related technologies project 2021-367 (to G.R., V.H.K.), of K.N. by Swiss National Science Foundation grants 220127 (to G.R.) and 201656, and ETH core funding (to G.R.), UZH core funding (to V.H.K) and funding by the Promedica Foundation grant F-87701-41-01 (to V.H.K).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the "Swiss Association of Research Ethics Committees" gave ethical approval for the data from the Tumor Profiler Study used in this work. The Tumor Profiler Study is an approved, observational clinical study (BASEC: 2018-02050, 2018-02052, 2019-01326).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
